Eli Lilly and Co. (NYSE:LLY) – Jefferies Group issued their Q3 2016 earnings estimates for shares of Eli Lilly and in a research note issued on Thursday. Jefferies Group analyst J. Holford expects that the firm will post earnings of $0.98 per share for the quarter. Jefferies Group currently has a “Buy” rating and a $105.00 target price on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2019 earnings at $5.61 EPS.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The company had revenue of $5.40 billion for the quarter, compared to analyst estimates of $5.14 billion. During the same period in the prior year, the firm posted $0.90 EPS. The business’s revenue was up 8.6% compared to the same quarter last year.
Other research analysts also recently issued reports about the stock. Leerink Swann reiterated a “buy” rating on shares of Eli Lilly and in a report on Sunday, June 26th. Argus increased their price objective on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Friday, July 29th. BMO Capital Markets restated a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Citigroup Inc. restated a “buy” rating on shares of Eli Lilly and in a report on Wednesday, August 3rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $97.06.
Eli Lilly and (NYSE:LLY) traded down 0.69% during mid-day trading on Friday, hitting $79.45. The stock had a trading volume of 1,356,558 shares. The company has a market capitalization of $84.03 billion, a P/E ratio of 34.25 and a beta of 0.17. The stock’s 50-day moving average is $79.70 and its 200 day moving average is $77.73. Eli Lilly and has a 52 week low of $67.88 and a 52 week high of $88.16.
In other news, major shareholder Lilly Endowment Inc sold 240,000 shares of the stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the transaction, the insider now owns 126,020,570 shares of the company’s stock, valued at approximately $10,443,324,635.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the transaction, the insider now directly owns 94,319 shares in the company, valued at approximately $7,674,737.03. The disclosure for this sale can be found here. Insiders own 0.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in LLY. Eaton Vance Management boosted its position in Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock worth $433,009,000 after buying an additional 2,307,920 shares during the period. Renaissance Technologies LLC boosted its position in Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock worth $159,402,000 after buying an additional 1,880,800 shares during the period. Beutel Goodman & Co Ltd. bought a new position in Eli Lilly and during the second quarter worth about $104,345,000. Janus Capital Management LLC boosted its position in Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock worth $789,162,000 after buying an additional 1,377,814 shares during the period. Finally, Vanguard Group Inc. boosted its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the period. 74.96% of the stock is currently owned by institutional investors.
About Eli Lilly and